🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 12 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 19/04/2017 | 115,55 | 116,63 | 114,29 | 114,63 | -0,02% | 2,03% | 1.570.400 |
| 18/04/2017 | 114,62 | 115,48 | 113,83 | 114,65 | -0,14% | 1,44% | 1.136.500 |
| 17/04/2017 | 114,39 | 115,23 | 113,95 | 114,81 | +0,89% | 1,12% | 1.183.700 |
| 13/04/2017 | 114,70 | 116,11 | 113,22 | 113,80 | -0,92% | 2,52% | 1.600.000 |
| 12/04/2017 | 114,23 | 115,80 | 113,69 | 114,86 | +0,55% | 1,85% | 1.161.900 |
| 11/04/2017 | 113,42 | 114,35 | 111,32 | 114,23 | +0,15% | 2,67% | 1.794.300 |
| 10/04/2017 | 115,66 | 116,66 | 112,94 | 114,06 | -1,57% | 3,22% | 2.116.600 |
| 07/04/2017 | 114,35 | 117,65 | 114,07 | 115,88 | +1,42% | 3,13% | 2.108.100 |
| 06/04/2017 | 114,11 | 114,88 | 113,17 | 114,26 | +0,13% | 1,50% | 1.959.300 |
| 05/04/2017 | 112,35 | 116,86 | 111,22 | 114,11 | +1,62% | 5,02% | 4.032.600 |
| 04/04/2017 | 107,24 | 112,69 | 107,24 | 112,29 | +4,50% | 5,08% | 2.913.800 |
| 03/04/2017 | 109,01 | 110,49 | 107,31 | 107,45 | -1,74% | 2,92% | 2.040.800 |
| 31/03/2017 | 107,89 | 109,49 | 106,54 | 109,35 | +1,92% | 2,73% | 2.849.200 |
| 30/03/2017 | 107,88 | 109,73 | 106,52 | 107,29 | -0,67% | 2,98% | 3.024.400 |
| 29/03/2017 | 106,03 | 111,88 | 106,03 | 108,01 | +20,45% | 5,52% | 13.681.500 |
| 28/03/2017 | 90,31 | 90,76 | 89,22 | 89,67 | -1,24% | 1,71% | 1.561.400 |
| 27/03/2017 | 89,28 | 91,49 | 88,90 | 90,80 | +0,91% | 2,90% | 1.383.200 |
| 24/03/2017 | 89,74 | 90,48 | 89,12 | 89,98 | +1,04% | 1,52% | 1.064.400 |
| 23/03/2017 | 90,00 | 90,75 | 88,94 | 89,05 | -1,10% | 2,01% | 1.043.600 |
| 22/03/2017 | 89,95 | 90,25 | 89,06 | 90,04 | +0,60% | 1,32% | 1.336.700 |
| 21/03/2017 | 91,81 | 91,83 | 89,44 | 89,50 | -1,98% | 2,60% | 1.711.800 |
| 20/03/2017 | 92,00 | 92,61 | 91,23 | 91,31 | -0,66% | 1,50% | 1.382.500 |
| 17/03/2017 | 92,97 | 93,50 | 91,76 | 91,92 | -0,48% | 1,87% | 2.501.000 |
| 16/03/2017 | 94,38 | 94,86 | 91,70 | 92,36 | -2,34% | 3,35% | 1.449.700 |
| 15/03/2017 | 93,21 | 95,00 | 93,13 | 94,57 | +1,97% | 2,01% | 1.031.400 |
| 14/03/2017 | 92,60 | 93,09 | 92,16 | 92,74 | -0,23% | 1,00% | 695.200 |
| 13/03/2017 | 94,24 | 94,24 | 92,93 | 92,95 | -1,10% | 1,39% | 897.600 |
| 10/03/2017 | 94,15 | 94,22 | 92,95 | 93,98 | +0,44% | 1,35% | 1.533.700 |
| 09/03/2017 | 92,45 | 93,60 | 91,96 | 93,57 | +1,51% | 1,77% | 1.217.100 |
| 08/03/2017 | 91,11 | 93,40 | 91,11 | 92,18 | +0,94% | 2,51% | 1.763.100 |